investigating long-term outcomes and predictors of primary outcomes in patients treated for cardiac implantable electronic device infections

Avrupa Kalp Ritim Derneği, Berlin, Almanya, 7 - 09 Nisan 2024, ss.503, (Özet Bildiri)

Background: The estimated current infection rate after cardiac implantable electronic devices (CIED) implantation ranges between 1% and

2%, with variations in the literature from 0.13% to 12.6% (2). The rise in CIED implantation rates over the years has led to an escalation in the

frequency of device-related infections. This trend is compounded by the elongation of patient comorbidities and life expectancy (3).

Purpose: The study aimed to investigate the primary outcome rates (including death, myocardial infarction (MI), cerebrovascular accidents

(CVA), and reinfection) and identify predictors of primary outcomes in patients receiving treatment for CIED infection.

Methods: A retrospective analysis was conducted at a single-center. The study encompassed 2322 patients who sought treatment at the

arrhythmia clinic of our Institute between March 2011 and July 2020 and underwent CIED implantation. After excluding 20 patients with active

infections and 3 patients postoperative cardiac arrest, 36 patients were diagnosed with CIED infection (1.55% incidence). Diagnosis was based

on the Novel 2019 International CIED Infection Criteria. Patients were categorized into groups based on the occurrence of all-cause death, MI,

CVA, and reinfection during the follow-up period.

Results: The median follow-up period post admission with CIED infection was 42.5 (7-141) months. Table 1 presents patient characteristics,

procedure details, and management-related parameters in the groups stratified by the primary endpoint. Notably, 58.3% of the patients had

previously undergone a replacement procedure. Among patients with CIED infection, reinfection was observed in 20.0% of those who had a de

novo procedure and 38.1% of those who underwent a secondary procedure (p: 0.25). Cox regression analysis revealed that pre-procedure

C-reactive protein (CRP) levels and CHA2DS2-VASc score were independent predictors of the primary outcome (OR: 1.03 (1.00-1.06); P:

0.035, OR: 1.34(1.03-1.88); P: 0.030, respectively) (Table 2).

Conclusion: Long-term outcomes in patients with CIED infection appear to be correlated with pre-procedure CRP levels, indicating the severity

of infection, and the CHA2DS2-VASc score, providing valuable insights into patient comorbidities. These factors seem to outweigh the impact of

the specific procedure and antibiotic regimens administered. Management should not only focus on the history of CIED infection during

follow-up but also prioritize the management of existing comorbidities to improve outcomes. Given the study's limitations such as the small

sample size and retrospective nature, further investigations are warranted to confirm these findings.